The antimalarial agent, artesunate has been observed to suppress the infection growth rate of Plasmodium berghei in CF, mouse red blood cells. The inhibition of growth was due to a number of biochemical mechanisms. Deoxyribonucleic acid (DNA) synthesis in the Plasmodium berghei was inhibited significantly by the drug with marginal inhibition of protein synthesis. The inhibition of DNA synthesis seemed to be due to a block of purine synthesis at the regulatory enzyme site of inosine monophosphate (IMP) dehydrogenase. Whereas there was no evidence to demonstrate that the drug alkylated nucleotide bases or caused cross linking of DNA strands of the plasmodium, the drug did appear to cause non-specific binding to bases that interfered with template activity. There was marked inhibition of messenger ribonucleic acid (mRNA) polymerase activity with moderate inhibition of DNA polymerase activity. The drug caused significant reduction of basal oxygen consumption of Plasmodium berghei with a significant inhibition of succinic acid dehydrogenase activity. The drug interacted with reduced nicotinamide adenine dinucleotide (NADH ), suggesting the possibility that artesunate may interfere with energy required for cell growth.
Introduction
The Chinese herb Artemisia annua which is a member of the Compositae family, contains an active principle, Arteannuin (qinghaosu, QHS, artemisinie) which has been shown to have antimalarial activity in vivo.2,3) A number of its derivatives, e.g. dihydroqinghaosu (DHQ), artemether, and a-propoxycarboxydihydroartemisinin (SM242) have been synthesized and also investigated for antimalarial activity in the United States and Britain. 4, 5) Qinghaosu is relatively insoluble in biological aqueous medium; however, the agent artesunate which has been used in the People's Republic of China to treat malaria has been reported to not only be soluble in an aqueous sodium, but more potent than DHQ.2,3) Artesunate has been shown to be active against chloroquine-resistant and -sensitive strains of Plasmodium berghei,2) Plasmodium knowlesi,2) and Plasmodium falciparum4) as well as cerebral malaria infections.
Thus we selected artensunate as a proto-type drug of the qinghaosu chemical class in order to study its in vitro metabolic effects on Plasmodium berghei. Infected red blood cells (RBC) from CF, mice were used since this rodent species acted as a suitable host for the plasmodium. These results are reported at this time.
Experimental Source of Drug
Artesunate was obtained as a white crystalline powder in ampules of 100 and 500 mg quantities from the Pharmaceutical Factory of Guilin, Guangxi, People's Republic of China and the drug is reported to be greater than 99% pure. direct alkylation of the bases by the drug in the concentration range of 10 30 pm. Studies with Plasmodium berghei incubating with drug for 24 h showed that the drug did not cause cross linking of DNA strands of Plasmodium berghei but did result in DNA strand scission at 10-4 m concentration (Fig. 4) . These studies were repeated twice affording similar results. DNA viscosity and DNA thermal denaturation studies demonstrated only minimal binding of the drug to DNA; however, the binding did not appear to be by cross linking of the two strands (Fig. 5) .
Protein synthesis was also suppressed by artesunate; however, this inhibition was not of the same magnitude as the observed DNA synthesis inhibition and probably only accounted for moderate inhibition of plasmodium growth. The effects on protein synthesis appeared to be afforded by the drug at the initiation steps of the protein synthesis process since the pattern of inhibition resembles that of pyrocatechol violet more so than emetine, as reference standards (Fig. 6 ).
Infected RBC with P. berghei demonstrated a much higher rate of basal respiration than non-infected RBC normal cells (results not shown). Artesunate at 3 x 10-6 M concentration 
